Cargando…
Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA
The adult attention-deficit/hyperactivity disorder (ADHD) quality-of-life (AAQoL) scale was previously validated in adult patients in the USA; here, the AAQoL is validated in adult European patients. Data from a 12-week open-label acute treatment period with atomoxetine (80–100 mg/day) in adults wit...
Autores principales: | Brod, Meryl, Adler, Lenard A., Lipsius, Sarah, Tanaka, Yoko, Heinloth, Alexandra N., Upadhyaya, Himanshu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449381/ https://www.ncbi.nlm.nih.gov/pubmed/25563210 http://dx.doi.org/10.1007/s12402-014-0160-z |
Ejemplares similares
-
Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine
por: Upadhyaya, Himanshu, et al.
Publicado: (2013) -
Underdiagnosis of Attention-Deficit/Hyperactivity Disorder in Adult Patients: A Review of the Literature
por: Ginsberg, Ylva, et al.
Publicado: (2014) -
Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials
por: Asherson, Philip, et al.
Publicado: (2014) -
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009) -
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
por: Clemow, David B, et al.
Publicado: (2017)